A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis.
Cholangitis
Immune checkpoint inhibitors
Large cell carcinoma
Pembrolizumab
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
07
2020
revised:
12
08
2020
accepted:
13
08
2020
entrez:
18
9
2020
pubmed:
19
9
2020
medline:
19
9
2020
Statut:
epublish
Résumé
Large-cell carcinoma (LCC) of the lung is defined as an undifferentiated non-small cell lung cancer (NSCLC) and accounts for approximately 7.5% of lung cancers. Immune checkpoint inhibitors (ICIs) may be effective for LCC, but there has been no firm evidence due to its low frequency. We herein report an 80-year-old woman with LCC of the lung who was successfully treated with pembrolizumab but developed sclerosing cholangitis as an immune-related adverse event. This case highlights the efficacy of ICIs for LCC as well as the importance of the immediate and detailed management of ICI-related sclerosing cholangitis.
Identifiants
pubmed: 32944497
doi: 10.1016/j.rmcr.2020.101197
pii: S2213-0071(20)30411-1
pii: 101197
pmc: PMC7481563
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101197Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
All the authors have no conflict of interest about this case report.
Références
Semin Diagn Pathol. 2019 Nov;36(6):434-440
pubmed: 31358424
Cancer Treat Rev. 2016 Mar;44:51-60
pubmed: 26874776
Hepatol Res. 2017 Oct;47(11):1102-1107
pubmed: 27874998
Invest New Drugs. 2017 Aug;35(4):529-536
pubmed: 28317087
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
ESMO Open. 2017 Oct 10;2(4):e000268
pubmed: 29081991
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Thorac Oncol. 2019 Jul;14(7):1213-1222
pubmed: 30978501
Hepatology. 2019 Feb;69(2):914-916
pubmed: 30033637
Hepatol Res. 2019 Aug;49(8):950-956
pubmed: 30861263
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
Eur J Cancer. 2019 Jul;115:107-110
pubmed: 31132740
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
ESMO Open. 2018 Jan 13;3(1):e000278
pubmed: 29387476
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Ann Oncol. 2016 Apr;27(4):559-74
pubmed: 26715621
Jpn J Clin Oncol. 2017 Feb 11;47(2):175-178
pubmed: 28173241
Histopathology. 2020 Feb;76(3):470-480
pubmed: 31550390
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Int J Cancer. 2017 Sep 1;141(5):1018-1028
pubmed: 28263392
World J Gastroenterol. 2020 Jan 21;26(3):353-365
pubmed: 31988594
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921